Search Results

You are looking at 31 - 40 of 954 items for :

  • "breast cancer" x
Clear All
Full access

Amy Cyr

The management of early-stage breast cancer is becoming less and less invasive, according to Amy Cyr, MD, Assistant Professor of Surgery at Washington University School of Medicine and an oncologic surgeon at the Siteman Cancer Center at Barnes

Full access

Metastatic Breast Cancer, Version 1.2012

Featured Updates to the NCCN Guidelines

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar and Dorothy A. Shead

NCCN Guidelines Insights : Metastatic Breast Cancer, Version 1.2012 Version 1.2012 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without

Full access

Therese B. Bevers

– 5687 . 2. Lamb CA Helguero LA Fabris V . Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma . Breast Cancer Res Treat 2003 ; 79 : 25 – 35 . 3. Sporn MB Dowsett SA Mershon J Bryant HU

Full access

Matthew Ellis

Deep genomic analysis of breast cancer tumors should soon result in new therapeutic road maps, with treatment paradigms based on a pharmacopeia of cell-type and pathway-matched therapies. Individual cases of breast cancer will ultimately be

Full access

Tomas G. Lyons and Mark E. Robson

. Evolution of PARP Targeting in Breast Cancer There are currently a number of PARPi in clinical development, including olaparib, veliparib, niraparib, rucaparib, and talazoparib. These PARPi are similar in that they all inhibit PARP1 and PARP2 catalytic

Full access

Adrienne G. Waks and Ann H. Partridge

in women of child-bearing age with breast cancer Outline both the established and emerging techniques for fertility preservation Review the barriers in fertility preservation and available data on the safety of pregnancy in breast cancer survivors

Full access

Jason P. Wilson, David Mattson and Stephen B. Edge

A lthough the involvement of axillary nodes remains a significant prognostic factor used in the management of breast cancer, the management of the axilla has changed dramatically. Among women with clinically negative nodes, the National Surgical

Full access

Aki Morikawa and Andrew D. Seidman

Contemporary systemic therapy is commonly informed by the classification of breast cancer based solely on hormonal receptor and HER2 status. Triple-negative is a category of exclusion defined by immunohistochemical and/or fluorescence in situ

Full access

Stefanie S. Jeffrey, Per Eystein Lønning and Bruce E. Hillner

– 424 . 4 Yarden Y Baselga J Miles D . Molecular approach to breast cancer treatment . Semin Oncol 2004 ; 31 ( suppl 10 ): 6 – 13 . 5 Perou CM Jeffrey SS van de Rijn M . Distinctive gene expression patterns in human mammary

Full access

Kathryn J. Ruddy, Lindsey Sangaralingham, Rachel A. Freedman, Sarah S. Mougalian, Heather Neuman, Caprice Greenberg, Ahmedin Jemal, Narjust Duma, Tufia C. Haddad, Valerie Lemaine, Karthik Ghosh, Tina J. Hieken, Katie Hunt, Celine Vachon, Cary P. Gross and Nilay D. Shah

Breast cancer survivors who have residual breast tissue are recommended to undergo mammographic surveillance annually. ASCO, the American Cancer Society (ACS), and NCCN recommend annual mammograms beginning at 1 year after the mammogram that led